1, strictly grasp the indications for treatment: for patients with mild hepatic inflammatory lesions, it is difficult to achieve a sustained response (such as ALT normal, HBeAg positive immune tolerance), especially (when these patients <30 years old), should try to avoid the use of nucleoside (acid) analogues treatment. 2, careful selection of nucleoside (acid) analogues: if conditions permit, it is advisable to start treatment with drugs that have a strong antiviral effect and a low incidence of drug resistance. Close monitoring and timely combination therapy: HBV DNA should be tested regularly to detect primary non-response or virological breakthrough in time. For patients with poor early response such as combined HIV infection, cirrhosis and high viral load, it is advisable to adopt nucleoside (acid) drug combination therapy without cross-resistance sites as early as possible. 4. Once drug resistance is detected, rescue therapy should be given as early as possible: for patients treated with lamivudine, adefovir combination therapy should be added once genotypic resistance is detected or HBV DNA begins to rise, which will result in faster suppression of the virus, less occurrence of drug resistance, and a better clinical outcome. There are relatively few clinical studies on the treatment of patients with resistance to other drugs, and recommendations regarding treatment are based primarily on the results of in vitro studies. For patients with resistance to telbivudine and entecavir, combination therapy with adefovir can be added. For adefovir-resistant patients, combination therapy with lamivudine and telbivudine can be added; for those who have not used other nucleoside analogs, entecavir can also be switched. For those who have not used other nucleoside analogs, they can also switch to entecavir. For those who are resistant to nucleoside (acid) analogs, they can also consider switching to or adding interferon analogs for combination therapy, but they should avoid the combination of tibivudine and PEG-IFN because it can lead to peripheral neuromuscular diseases. 5, try to avoid single-drug sequential treatment: some clinical studies have shown that, because of a nucleoside (acid) class resistance and successive switch to other glycosides (acid) class drug treatment, can be screened for a variety of glycoside (acid) class resistance to the mutant strain. Therefore, single-drug sequential therapy should be avoided.